A phase 2 study of SR-0379 in patients with cutaneous ulcer (pressure ulcer, diabetic ulcer)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223939

Enrollment

120

Registered

2018-06-12

Start date

2018-07-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous ulcer (pressure ulcer, diabetic ulcer)

Interventions

investigational material(s) Generic name etc : SR-0379 INN of investigational material : - Therapeutic category code : 269 Other agents for epidermis Dosage and Administration for Investigational mate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose major axis of ulcer is 1 cm or more and 6 cm or less, and depth of ulcer is classified into d2, D3, or D4 referring to the DESIGN-R(R) for evaluation of pressure ulcer (Japanese Society of Pressure Ulcers), etc.

Exclusion criteria

Exclusion criteria: Patients who have ulcer with apparent infection including flare, swelling, pus, malodor, or fever around the ulcer, etc.

Design outcomes

Primary

Measure	Time frame
efficacy The percent reduction in surface area of the ulcer	—

Secondary

Measure	Time frame
safety Percentage of patients with any adverse events, etc.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026